FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to ophthalmology, and is intended for the prevention and treatment of early manifestations of age-related nuclear cataract. The eye drops contain, as an active ingredient, a serotonin receptor antagonist, namely ondansetron hydrochloride dihydrate, in a wider reduced dosage range. Additionally, they contain auxiliary components that increase the prophylactic and therapeutic effect of small doses of the active component: a prolonger of contact time with the ocular surface, a pH regulator of the medium, a stabilizer of biological, physicochemical properties and / or resistance to contamination by microorganisms. The components are used in the stated quantities.
EFFECT: use of the invention provides the creation of improved eye drops with a metered prophylactic and therapeutic anti-dystrophic effect, which is due to the optimal physicochemical properties of the solution, facilitating the penetration of small doses of the active component into the intraocular structures.
9 cl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| EYE DROPS FOR TREATING AGE-RELATED NUCLEAR CATARACT | 2019 |
|
RU2720676C2 |
| NEW EYE DROPLETS FOR CONSERVATIVE TREATMENT AND PREVENTION OF THE AGE-RELATED NUCLEAR CATARACT | 2015 |
|
RU2637875C2 |
| METHOD OF CONSERVATIVE TREATMENT AND PREVENTION OF NUCLEAR TYPE OF AGE CATARACT | 2009 |
|
RU2411926C2 |
| METHOD OF CONSERVATIVE TREATMENT AND PREVENTION OF CORTICAL TYPE OF AGE CATARACT | 2009 |
|
RU2418568C2 |
| METHOD FOR EXPERIMENTAL IN VIVO SIMULATION OF CORTICAL CATARACT | 2011 |
|
RU2553577C2 |
| METHOD FOR PREDICTION OF AGE-SPECIFIC CATARACT TYPE PRIOR TO CONTRACTION THEREOF | 2008 |
|
RU2371098C1 |
| EYE DROPS | 2009 |
|
RU2404768C1 |
| DRUG PREPARATION FOR TREATING CATARACT AND METHOD FOR PREPARING IT (VERSIONS) | 2012 |
|
RU2536958C2 |
| EYE DROPS FOR CATARACT TREATMENT | 1993 |
|
RU2071316C1 |
| METHOD FOR CATARACT TREATMENT AND EYE DROPS FOR IMPLEMENTATION THEREOF | 2016 |
|
RU2662364C2 |
